Alpha Tau price target raised to $9 from $7 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Alpha Tau (DRTS) to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s “broader-than-expected” Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See the top stocks recommended by analysts >>
Read More on DRTS:
- Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses
- Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
- Alpha Tau downgraded to Neutral from Overweight at Piper Sandler
- DRTS Earnings this Week: How Will it Perform?
- Alpha Tau Lands First International Approval as Japan Grants Marketing Clearance for Alpha DaRT (NASDAQ: DRTS)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
